Moderna, Inc. (MRNA)
| Market Cap | 39.15B |
| Revenue (ttm) | 6.85B |
| Net Income (ttm) | -4.71B |
| Shares Out | 382.88M |
| EPS (ttm) | -12.33 |
| PE Ratio | n/a |
| Forward PE | 32.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 795,985 |
| Open | 102.53 |
| Previous Close | 103.44 |
| Day's Range | 99.90 - 103.51 |
| 52-Week Range | 62.55 - 144.43 |
| Beta | 1.59 |
| Analysts | Hold |
| Price Target | 132.00 (+29.03%) |
| Earnings Date | May 2, 2024 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $132.0, which is an increase of 29.03% from the latest price.
News
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its f...
Moderna Betrays Africa, Says AHF
LOS ANGELES--(BUSINESS WIRE)-- #Africa--AIDS Healthcare Foundation (AHF) says Moderna's promise to build a state-of-the-art mRNA manufacturing facility in Africa in 2022 was nothing more than a self-s...
Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.
Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps
Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines.
Among the biggest winners today are some major long-term losers, says Jim Cramer
'Mad Money' host Jim Cramer looks at today's market winners and losers.
Moderna Reports Positive Results from Cancer Vaccine-Keytruda Combination Trial
Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA ca...
Moderna's stock jumps 6% as its cancer vaccine could treat more than just melanoma
Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.
What made Moderna stock pop 10% on Tuesday?
Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.
Moderna jumps as personalized cancer vaccine shows benefit in early study
Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of he...
Moderna shares fall after judge sides with Arbutus in patent fight
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, eva...
Three top U.S. biotech stocks to buy in April
“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
Moderna CEO talks China investment, vaccine updates to boost growth post-pandemic
Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-ov...
Moderna Gets $750 Million in Flu Shot Funding, Stock Advances
Moderna Inc. (MRNA) shares advanced Wednesday as the biotech firm used its “Vaccines Day” event to make key announcements about new funding and the results of several vaccine trials.
Moderna shares continue to fall even as its 3 vaccines enter final stage trials
Moderna Inc. saw its stock continue its downward trajectory on Wednesday morning, slipping by 1.2 percent to $106.21, following a decline of over 3 percent on Tuesday. The biotech company's shares hav...
CARsgen Announced 2023 Annual Results
SHANGHAI , March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematol...
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston.
Moderna CEO on vaccines pipeline: Investing aggressively to bring important medicine to patients
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's annual vaccines day, the announcement of multiple vaccine programs advancing to late-stage clinical trials, Moderna's vaccines p...
Moderna Gets $750 Million for Flu Program. Funding to Help Move Beyond Covid Vaccines.
The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.
Moderna gets $750 mln funding from Blackstone Life Sciences to develop flu shots
Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.
Blackstone Life Sciences Announces Collaboration to Support Moderna's Influenza Program
NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where fun...
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine a...
Moderna Says 'Next-Generation' COVID-19 Shot Had Positive Phase 3 Test Results
Moderna Inc. (MRNA) on Tuesday reported "positive interim results" from a late-stage study of what it calls the "next-generation COVID-19 vaccine."
Moderna says new Covid vaccine showed stronger immune response than current shot in study
Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.
Moderna Stock Pops as New Covid-19 Vaccine Shows Positive Results
Moderna's ‘next generation,' Covid-19 vaccine has shown a higher immune response to the virus than the current version of the shot.